IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial. (IDOvaccine)

NCT01219348 Phase 1 COMPLETED

Title: IDO peptid vaccination in combination with immune stimulating agent Aldara and the adjuvant Montanide, for treatment of patients with locally advanced or metastatic non small-cell lung cancer. A first-in-man phase I trial. Hypothesis: In this trial the investigators assess a new immunotherapeutic strategy targeting the immune inhibiting enzyme, IDO to investigate the potential of vaccination against IDO as a possible anticancer target.

Details

Lead sponsor	Inge Marie Svane
Phase	Phase 1
Status	COMPLETED
Enrolment	14
Start date	2010-06
Completion	2012-08

Conditions

• NSCLC
• Lung Cancer

Interventions

• IDO peptide vaccination

Primary outcomes

• evidence of toxicity — 12 months
  CTCAE = Common Terminology Criteria for Adverse Events v. 3.0 will be used for registration of toxicity

Countries

Denmark